Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Grunenthal

              • Development Update

              Virtual BoothOur shared vision is to have a World, free of Pain.

              GERMANY Germany

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Peripheral NOP Agonist Addressing Chronic Peripheral Neuropathic Pain Enters Clinical Development

              Contact the Supplier

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 16, 2020

              Details:

              The Phase I trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of an investigational peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist following single and multiple-ascending doses.

              MODAG

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease

              Contact the Supplier

              Lead Product(s): Anle138b

              Therapeutic Area: Neurology Product Name: Anle138b

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 23, 2020

              Details:

              The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in e clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).

              MODAG

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              MODAG Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation

              Contact the Supplier

              Lead Product(s): Anle138b

              Therapeutic Area: Neurology Product Name: Anle138b

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson's Research.

              Deal Size: $1.4 million Upfront Cash: Undisclosed

              Deal Type: Funding August 05, 2020

              Details:

              Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in animal models.

              PharmaCompass__DigitalAd